Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (71-80 of 201) with videos related to

Pageof 21
Sort By:
Fertility and Sterility|January 6, 2015
Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1Vanessa L Merker, Timothy P Murphy, J Bryan Hughes, et al.
Journal of Neurosurgery|October 30, 2012
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1Gavin P Dunn, Konstantinos Spiliopoulos, Scott R Plotkin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 11, 2012
Emotional functioning of patients with neurofibromatosis tumor suppressor syndromeDaphne L Wang, Kelly B Smith, Sonia Esparza, et al.
Gait & Posture|June 15, 2026
Reliability of a modified mini balance evaluation systems test (Mini-BESTest) in NF2-related schwannomatosisNatalie E Stec, David G Bonilla, Taya Hamilton, et al.
Neurobiology of Disease|October 27, 2007
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growthMarianne F James, Johanna M Lelke, Mia Maccollin, et al.
Skeletal Radiology|December 8, 2011
Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosisJacob L Jaremko, Peter J MacMahon, Martin Torriani, et al.
Neuro-Oncology Advances|March 13, 2024
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in <i>NF2</i>-deficient modelsSrirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, et al.
Radiology|February 27, 2009
Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR imagesWenli Cai, Ara Kassarjian, Miriam A Bredella, et al.
Journal of Neuro-Oncology|December 1, 2016
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosisMojtaba Talaei-Khoei, Eric Riklin, Vanessa L Merker, et al.
Journal of Neuro-Oncology|January 7, 2015
Examining perceived cancer risk among patients with neurofibromatosis type 1Elyse R Park, Kelly B Smith, Vanessa L Merker, et al.
Pageof 21

Showing results (71-80 of 201) with videos related to

Sort By:
Pageof 21
Fertility and Sterility|January 6, 2015
Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1Vanessa L Merker, Timothy P Murphy, J Bryan Hughes, et al.
Journal of Neurosurgery|October 30, 2012
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1Gavin P Dunn, Konstantinos Spiliopoulos, Scott R Plotkin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 11, 2012
Emotional functioning of patients with neurofibromatosis tumor suppressor syndromeDaphne L Wang, Kelly B Smith, Sonia Esparza, et al.
Gait & Posture|June 15, 2026
Reliability of a modified mini balance evaluation systems test (Mini-BESTest) in NF2-related schwannomatosisNatalie E Stec, David G Bonilla, Taya Hamilton, et al.
Neurobiology of Disease|October 27, 2007
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growthMarianne F James, Johanna M Lelke, Mia Maccollin, et al.
Skeletal Radiology|December 8, 2011
Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosisJacob L Jaremko, Peter J MacMahon, Martin Torriani, et al.
Neuro-Oncology Advances|March 13, 2024
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in <i>NF2</i>-deficient modelsSrirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, et al.
Radiology|February 27, 2009
Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR imagesWenli Cai, Ara Kassarjian, Miriam A Bredella, et al.
Journal of Neuro-Oncology|December 1, 2016
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosisMojtaba Talaei-Khoei, Eric Riklin, Vanessa L Merker, et al.
Journal of Neuro-Oncology|January 7, 2015
Examining perceived cancer risk among patients with neurofibromatosis type 1Elyse R Park, Kelly B Smith, Vanessa L Merker, et al.
Pageof 21